R. Maciuca

发表

How Do Heuristics Expedite Markov Chain Search? Hitting-time Analysis of the Independence Metropolis Sampler

Song-Chun Zhu, R. Maciuca, 2003 .

First Hitting Time Analysis of the Independence Metropolis Sampler

Song-Chun Zhu, R. Maciuca, 2006 .

OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study.

R. Maciuca, J. Mansfield, D. Rubin, 2017, Journal of Crohn's & colitis.

Etrolizumab Treatment Leads to Early Improvement in Symptoms and Inflammatory Biomarkers in Anti-TNF-refractory Patients in the Open-Label Induction Cohort of the Phase 3 Hickory Study

R. Maciuca, J. Mansfield, D. Rubin, 2017 .

20 ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT

R. Maciuca, D. Rubin, L. Peyrin-Biroulet, 2018 .

PWE-071 Etrolizumab induction in moderate/severe anti-TNF intolerant/refractory (IR) UC: the hickory open-label induction (OLI) trial

R. Maciuca, D. Rubin, B. Hayee, 2018, IBD.

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10

Shan V Andrews, R. Maciuca, L. Przybyla, 2021, Scientific reports.

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

R. Maciuca, K. Kalunian, John C. Davis, 2015, Annals of the rheumatic diseases.

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

R. Maciuca, M. Bijl, F. Houssiau, 2013, Arthritis and rheumatism.

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

R. Maciuca, B. Rovin, L. Hebert, 2013, Clinical journal of the American Society of Nephrology : CJASN.

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Nicholas E. Propson, R. Maciuca, K. Scearce-Levie, 2022, Science Translational Medicine.

Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers

R. Maciuca, A. Ascherio, G. Astarita, 2020, Neurology.

Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials

R. Maciuca, P. Korenblat, N. Hanania, 2014 .

Assessment of Disease‐Related Therapeutic Protein Drug‐Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis

R. Maciuca, J. Kenny, L. Dickmann, 2016, Journal of clinical pharmacology.

FRI0293 Validation of the revised selena flare index in systemic lupus erythematosus

R. Maciuca, M. Petri, J. Davis, 2013 .

Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma

R. Maciuca, L. Boulet, P. O'Byrne, 2012 .

Effect Of An Anti-M1 Prime Monoclonal Antibody, MEMP1972A, In A Phase II Proof-Of-Activity Allergen Challenge Study In Patients With Mild Asthma

R. Maciuca, L. Boulet, P. O'Byrne, 2012, ATS 2012.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

R. Maciuca, P. Korenblat, N. Hanania, 2015, Thorax.

LRRK2 Kinase Activity Regulates Parkinson’s Disease-Relevant Lipids at the Lysosome

Nicholas E. Propson, Michelle L. Reyzer, R. Maciuca, 2022, bioRxiv.

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

R. Maciuca, L. Boulet, P. O'Byrne, 2014, Science Translational Medicine.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

R. Maciuca, B. Rovin, J. Sánchez-Guerrero, 2012, Arthritis and rheumatism.

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10

R. Maciuca, L. Przybyla, M. Maloney, 2021, Scientific Reports.

Late breaking abstracts

R. Maciuca, D. Rubin, J. Bohr, 2017 .

Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial Injury

R. Maciuca, D. Danilenko, M. Rothenberg, 2018, Clinical pharmacology and therapeutics.

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE

Christina Chaivorapol, Alyssa Morimoto, Timothy W Behrens, 2015, Lupus Science & Medicine.

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

R. Maciuca, K. Scearce-Levie, D. Jennings, 2023, Movement disorders : official journal of the Movement Disorder Society.

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

R. Maciuca, Alexander R. Abbas, D. Wallace, 2012, Arthritis and rheumatism.

Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma.

Christopher R. Cabanski, R. Maciuca, S. Mosesova, 2016, The Journal of allergy and clinical immunology.

Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs

R. Maciuca, T. Nicholas, D. Burn, 2020, Clinical pharmacology and therapeutics.

P132 Analysis of various central endoscopy reading methodologies in the BERGAMOT exploratory induction cohort evaluating etrolizumab in Crohn’s Disease

R. Maciuca, D. Mishkin, W. Reinisch, 2018 .

A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

Christopher R. Cabanski, R. Maciuca, I. Agache, 2016, Respiratory Research.

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

R. Maciuca, K. Scearce-Levie, Y. Ran, 2023, bioRxiv.

Treatment With MEMP1972A, An Anti-M1 Prime Monoclonal Antibody, Reduced Serum IgE In Healthy Volunteers And Patients With Allergic Rhinitis

R. Maciuca, J. Matthews, Jeffrey M Harris, 2012, Asian Test Symposium.

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

R. Maciuca, K. Scearce-Levie, Y. Ran, 2024, bioRxiv.